• SepM Mutations in S. mutans Clinical Isolates

  2026-08-11

  Liu et al. investigated how naturally occurring sepM mutations in Streptococcus mutans clinical isolates influence antagonism toward Streptococcus gordonii. Their combination of clinical isolate genotyping, expression analysis, recombinant protein studies, and CSP-21 binding measurements linked selected missense variants to stronger, pH-dependent SepM–CSP-21 interactions.

• JXY, TLR4, and M1 Polarization in Colitis-Associated CRC

  2026-08-11

  Liu et al. show that Jiedu Xiaozheng Yin (JXY) limits colitis-associated colorectal cancer progression in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. The study combines an orthotopic cancer model with macrophage assays, providing a framework for connecting tumor burden, immune-cell polarization, inflammatory gene expression, and pathway perturbation.

• Anlotinib Hydrochloride: Translating Angiogenesis Biology

  2026-08-10

  An evidence-led perspective on how Anlotinib hydrochloride connects VEGFR2, PDGFRβ, and FGFR1 inhibition with endothelial phenotypes, ERK pathway control, assay strategy, and translational decision-making in cancer research.

• Imatinib hydrochloride: Applied Assay Workflows

  2026-08-09

  Build more informative kinase-inhibition studies with Imatinib hydrochloride by pairing dose–response data with pathway-proximal and orthogonal readouts. This workflow distinguishes v-Abl, c-Kit, and PDGFR dependence from nonspecific loss of viability while using the latest kinase–phosphatase findings to refine assay interpretation.

• Anlotinib VEGFR2 Inhibition: Preclinical Evidence

  2026-08-08

  The reference study established anlotinib as a potent, orally active VEGFR2 inhibitor that suppresses tumor angiogenesis across biochemical, cellular, ex vivo, and animal models. Its most important translational insight is the separation between highly sensitive endothelial responses and weaker direct effects on tumor-cell proliferation, supporting an angiogenesis-centered mechanism of action.

• Cannabidiol in Orofacial Inflammatory Pain: Mechanisms

  2026-08-07

  This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both nociceptive and pain-related affective abnormalities in mouse inflammatory pain models. Its central contribution is the integration of peripheral cannabinoid, trigeminal, cortical, endocannabinoid, and amygdala serotonergic measurements within a single experimental framework, while also identifying important limits for translation to receptor-specific therapies.

• Anlotinib Hydrochloride: Applied Use in Angiogenesis Assays

  2026-08-07

  Anlotinib hydrochloride accelerates anti-angiogenic research through ultra-selective, multi-target tyrosine kinase inhibition. Its low cytotoxicity and robust inhibition of VEGFR2, PDGFRβ, and FGFR1 position it as a superior choice for endothelial migration and tube formation assays, enabling more reproducible, high-sensitivity cancer research outcomes.

• Cabozantinib (XL184): Systems Biology Insights and Practical

  2026-08-06

  Explore the systems-level impact of Cabozantinib (XL184) on receptor tyrosine kinase signaling, with unique emphasis on translational phosphoproteomics, protocol optimization, and assay design for medullary thyroid and renal cell carcinoma research.

• Pentoxifylline Suppresses Hyperinflammation in Preterm Monoc

  2026-08-06

  Schüller et al. provide the first in vitro evidence that pentoxifylline (PTX) modulates LPS-induced hyperinflammatory responses in monocytes from preterm infants by downregulating key surface markers, cytokine production, and TLR4 signaling. These findings reveal age-dependent immunomodulatory effects with potential implications for adjunctive sepsis therapy in neonates.

• E-64d: Precision Cysteine Protease Inhibition in Cell Death

  2026-08-05

  E-64d enables targeted, membrane-permeable cysteine protease inhibition for dissecting calpain- and cathepsin-driven cell death pathways, including lysoptosis and apoptosis, in both cellular and animal models. This article details robust experimental workflows, troubleshooting strategies, and the translational impact of recent discoveries, empowering researchers to achieve reproducible, interpretable results with APExBIO's high-purity E-64d.

• Acetylcholine Chloride in Gut-Brain Cholinergic Pathway Rese

  2026-08-05

  Acetylcholine Chloride empowers high-fidelity modeling of gut-brain cholinergic circuits, enabling translational breakthroughs in neuromuscular and neurogastroenterology research. Advanced workflows, troubleshooting guidance, and protocol refinements help researchers decode microbiota-brain interactions and optimize experimental reproducibility.

• Branched Lipids Enhance mRNA and RNP Delivery for Gene Editi

  2026-08-04

  The reference study introduces branched endosomal disruptor (BEND) lipids that markedly improve the cytosolic delivery of mRNA and CRISPR-Cas9 RNP complexes. This innovation addresses key bottlenecks in hepatic gene editing and T cell engineering by optimizing endosomal escape, with broad implications for the clinical translation of mRNA therapeutics.

• Sunitinib: Multi-Targeted RTK Inhibitor for RCC Research Wor

  2026-08-04

  Leverage Sunitinib’s multi-pathway RTK inhibition to dissect tumor angiogenesis, drive apoptosis, and overcome resistance in renal cell carcinoma models. Explore practical protocol refinements, combination strategies, and troubleshooting methods that accelerate translational research and maximize the value of APExBIO’s Sunitinib in cutting-edge oncology studies.

• ETS1 Modulates Mitophagy via SENP2/HSPA8/FUNDC1 in BPD Model

  2026-08-03

  This study reveals that the transcription factor ETS1 mitigates bronchopulmonary dysplasia (BPD) by inhibiting mitochondrial damage-induced autophagy via the SENP2/HSPA8/FUNDC1 axis. These mechanistic insights highlight ETS1 as a regulator of mitophagy with potential impact on targeted BPD interventions.

• GDC-0941: Mechanistic Leverage and Strategic Value in PI3K I

  2026-08-03

  This thought-leadership article presents a comprehensive analysis of GDC-0941, a highly selective PI3K inhibitor, emphasizing the mechanistic underpinnings, translational research imperatives, and strategic guidance for oncology investigators. By integrating recent evidence, competitive perspectives, and future outlooks, the article provides actionable insights for designing robust experiments and advancing from bench to bedside.

14843 records 1/990 page Next 12345 下5页 Last page